Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort.
Maghnie M, Ranke MB, Geffner ME, Vlachopapadopoulou E, Ibáñez L, Carlsson M, Cutfield W, Rooman R, Gomez R, Wajnrajch MP, Linglart A, Stawerska R, Clayton PE, Darendeliler F, Hokken-Koelega ACS, Horikawa R, Tanaka T, Dörr HG, Albertsson-Wikland K, Polak M, Grimberg A. Maghnie M, et al. Among authors: wajnrajch mp. J Clin Endocrinol Metab. 2022 Nov 25;107(12):3287-3301. doi: 10.1210/clinem/dgac517. J Clin Endocrinol Metab. 2022. PMID: 36102184 Free PMC article.
Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial.
Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B; Transition Study Group. Mauras N, et al. Among authors: wajnrajch mp. J Clin Endocrinol Metab. 2005 Jul;90(7):3946-55. doi: 10.1210/jc.2005-0208. Epub 2005 Apr 26. J Clin Endocrinol Metab. 2005. PMID: 15855257 Clinical Trial.
A 4-Year, Open-Label, Multicenter, Randomized Trial of Genotropin® Growth Hormone in Patients with Idiopathic Short Stature: Analysis of 4-Year Data Comparing Efficacy, Efficiency, and Safety between an Individualized, Target-Driven Regimen and Standard Dosing.
Counts DR, Silverman LA, Rajicic N, Geffner ME, Newfield RS, Thornton P, Carakushansky M, Escobar O, Rapaport R, Levitsky L, Rotenstein D, Hey-Hadavi J, Wajnrajch MP. Counts DR, et al. Among authors: wajnrajch mp. Horm Res Paediatr. 2015;84(2):79-87. doi: 10.1159/000381642. Epub 2015 May 1. Horm Res Paediatr. 2015. PMID: 25966824 Free article. Clinical Trial.
A Genome-Wide Pharmacogenetic Study of Growth Hormone Responsiveness.
Dauber A, Meng Y, Audi L, Vedantam S, Weaver B, Carrascosa A, Albertsson-Wikland K, Ranke MB, Jorge AAL, Cara J, Wajnrajch MP, Lindberg A, Camacho-Hübner C, Hirschhorn JN. Dauber A, et al. Among authors: wajnrajch mp. J Clin Endocrinol Metab. 2020 Oct 1;105(10):3203-14. doi: 10.1210/clinem/dgaa443. J Clin Endocrinol Metab. 2020. PMID: 32652002 Free PMC article.
More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY.
Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, Hey-Hadavi J, Camacho-Hubner C, Wajnrajch MP, Valluri SR, Palladino AA, Gomez R, Salvatori R. Fleseriu M, et al. Among authors: wajnrajch mp. Eur J Endocrinol. 2021 Aug 27;185(4):525-538. doi: 10.1530/EJE-21-0239. Eur J Endocrinol. 2021. PMID: 34342594 Free PMC article.
52 results